Riparian Pharmaceuticals is an early stage biotechnology company employing innovative models of vascular pathophysiology to discover novel therapeutics. An Alumni of the JLab facility inBoston, Riparian is deploying hemodynamics as a tool to discover first in class therapeutics acting on new pathways at an earlier stage of disease than is possible today. Despite prolific, effective and safe medicines for classical risk factors such as dyslipidemia, hypertension, and hyperglycemia, cardiovascular disease remains the leading cause of human mortality. In the natural world, the riparian zone is a unique rich ecosystem created through the interaction of a river with its banks. In the human body, moving blood, or hemodynamics, similarly interacts with the walls of blood vessels generating unique biological activity. This very interaction, between hemodynamics and the vascular wall, is a critical and unexplored determinant of vascular health.
